GlassScriptPhysician profile
David H Weinstein
NPI 1982751236
$3,729.79
in general payments reported to CMS, 2019-2025
16 companies · $663 in 2025
The $663 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,039 · 2020: $41.63 · 2021: $295 · 2022: $580 · 2023: $505 · 2024: $605 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,742 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,741.63 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,376.63 | 2019-2025 | |
| Abbvie INC. | $1,207.28 | 2019-2025 | Skyrizi, Viberzi, Linzess |
| Genzyme Corporation | $449.41 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $167.94 | 2021-2024 | Entyvio |
| Qol Medical, LLC | $97.52 | 2021-2024 | Sucraid, Sucraid |
| Allergan, INC. | $71.85 | 2019 | |
| Celgene Corporation | $63.99 | 2021-2023 | Zeposia |
| Medtronic, INC. | $59.25 | 2023-2025 | Interstim, Pillcam |
| Merck Sharp & Dohme LLC | $57.81 | 2022-2024 | Dificid, Zinplava |
| Blueprint Medicines Corporation | $43.28 | 2023 | |
| Novo Nordisk INC | $32.27 | 2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.15 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.04 | 2023 | Cyltezo |
| Braintree Laboratories, INC. | $17.88 | 2021 | |
| Ironwood Pharmaceuticals, INC | $15.42 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $13.07 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.